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Gene amplification and protein overexpression of fibroblast growth factor receptor 2 (FGFR2) characterize the SUM-52 breast
cancer cell line developed in our laboratory. SUM-52 cells express nine distinct alternatively spliced isoforms of FGFR2. Among
these isoforms are twootherwise identical FGFR2variants that express either theC1orC3carboxyl terminus. FGFR2-C3variants are
not normally expressed by humanmammary epithelial (HME) cells, and we have shown that overexpression of FGFR2-C3 in HME
cells results in potent transformation. In particular, FGFR2-C3 expression leads to robust levels of constitutively tyrosine
phosphorylated FRS2 in the absence of ligand stimulation. In contrast, overexpressed FGFR2-C1 requires constant stimulationwith
exogenous keratinocyte growth factor (KGF) to mimic the signaling capability of FGFR2-C3. However, activation of FRS2 that
results from KGF-stimulated FGFR2-C1 signaling is transient and is associated with a mobility shift of FRS2 not observed when this
signaling molecule is activated by the C3 isoform of FGFR2. Mutation of the only tyrosine phosphorylated site present in the C1
terminus and absent fromC3, Tyr769, did not yield a receptor that rivaled the potent signaling of FGFR2-C3.We therefore conclude
that aberrant expression of alternatively spliced isoforms of FGFR2with the C3 carboxyl terminus in the SUM-52 breast cancer cells
results in sustained activation of signal transduction leading to transformation. J. Cell. Physiol. 210: 720–731, 2007.
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Significant progress has been made toward under-
standing the role of receptor tyrosine kinase signaling in
cancer. Receptor tyrosine kinases can acquire trans-
forming function via gene amplification, protein over-
expression, and/or mutations, leading to constitutive
activation and aberrant downstream signaling. The
fibroblast growth factor receptor (FGFR) family has
been found to play a role in the development of several
types of cancers. FGFR3 is often mutated in bladder
cancer, and occasionally in cervical and colorectal
cancers as well (Cappellen et al., 1999; Jang and Park,
2001). In gastric cancers, FGFR1, FGFR2, and FGFR4
have been shown to be overexpressed (Shin et al., 2000).
In particular, the splice variant FGFR2-IIIb, which will
be discussed in this article, is commonly gene amplified
and overexpressed in gastric cancers (Hattori et al.,
1990; Itoh et al., 1994). In regard to breast cancer,
studies have indicated that FGFR1, FGFR2, and
FGFR4 genes are occasionally amplified and over-
expressed, with the FGFR2-IIIb gene overexpressed in
approximately 5% of cases (Adnane et al., 1990; Penault-
Llorca et al., 1995). Beyond this, however, there is
limited understanding of a role of FGFR signaling in
human breast cancer.
SUM-52PE is a human breast cancer cell line
developed in our laboratory (Ethier et al., 1996). These
cells have gene amplification, and protein and message
overexpression of FGFR2. Specifically, SUM-52 cells
overexpress the IIIb splice variant of FGFR2, which is
the version expressed by epithelial cells and is the
receptor for keratinocyte growth factor (KGF). The
SUM-52 cells overexpress nine distinct isoforms of
FGFR2. Although all isoforms contain the Ig-IIIb
region in their ectodomain, they differ in the number
of the other immunoglobulin-like domains, the pre-
sence or absence of the acid box, and the carboxyl
terminal region. All three carboxyl termini (C1, C2,
and C3) are represented among the FGFR2 isoforms
expressed by the SUM-52 breast cancer cells (Tann-
heimer and Ethier, 2000). The C1 and C2 carboxyl
termini are alternatively spliced from the same exon,
whereas C3 is expressed from a separate exon (Itoh
et al., 1994). Normal human mammary epithelial cells
express only the full-length C1 isoform of FGFR2,
whereas expression of FGFR2 variants with the C3
carboxyl terminus has only been described in cancer
cells. Our work has focused on understanding the
differences in transforming function between two full-
length FGFR2 isoforms isolated from the SUM-52 cells
that differ only in their carboxyl termini (isoforms
C1#38 and C3#4). The C3 carboxyl terminus is
significantly shorter (11 amino acids in length) than
the C1 terminus (64 amino acids). There are 10 amino
acids common to both receptors’ carboxyl terminal
sequence, leaving only one amino acid unique to the C3
tail, and 54 on the C1 (Itoh et al., 1994). The FGFR2-C1
carboxyl terminus includes several tyrosine residues.
Among these, only the tyrosine at site 769 is known to
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be phosphorylated (homologous to Tyr766 on FGFR1),
and serves as a binding site for phospholipase C-g
(PLCg) as well as the Shb adapter protein, involved in
MAPK signaling (Mohammadi et al., 1991, 1996; Cross
et al., 2002).
Previously, we have stably overexpressed both
FGFR2 full-length variants (referred to as FGFR2-C1
and FGFR2-C3) in H16N2 human mammary epithelial
(HME) cells. Our results suggested that FGFR2-C3 is
more transforming than FGFR2-C1. Specifically, we
observed that FGFR2-C1-expressing cells grew poorly
under anchorage-independent conditions in the
absence of insulin. However, the FGFR2-C3-expres-
sing cells thrived in soft agar in the presence or
absence of insulin in their medium. Further, FGFR2-
C3 cells required a higher concentration of the FGFR
small molecule kinase inhibitor PD173074 to abrogate
their growth in soft agar, as compared to FGFR2-C1.
An additional significant phenotypic difference
between the isoforms was their ability to induce
invasion of basement membrane. We found that
the FGFR2-C3-expressing cells were able to invade at
similar rates as breast cancer cells, whereas the
FGFR2-C1-expressing cells were noninvasive (Moffa
et al., 2004).
Signaling through FGFR is mediated by the adapter
protein FGF receptor substrate 2 (FRS2). FRS2 is
myristoylated, and thus constitutively membrane-
bound (Kouhara et al., 1997). FRS2 is also bound to
FGFR, regardless of receptor activation status (Xu et al.,
1998). Once the receptor is activated by ligand binding,
FRS2 is tyrosine phosphorylated by FGFR and serves as
a docking site for other signaling molecules. Phosphory-
lated FRS2 binds to Grb2 and Shp2, leading to down-
stream activation of the PI3-K and MAPK pathways,
respectively (Kouhara et al., 1997; Hadari et al., 1998).
Our previous data indicated that the level of constitu-
tively tyrosine phosphorylated FRS2 was substantially
higher in the FGFR2-C3-expressing cells, as compared
to FGFR2-C1 cells. The intensity of ligand-independent
tyrosine phosphorylated FRS2 in the FGFR2-C3-
expressing cells was comparable to that observed in
the SUM-52 breast cancer cells. In the FGFR2-C1 cells,
however, the level of tyrosine phosphorylated FRS2 was
low in the absence of KGF stimulation (Moffa et al.,
2004).
In this work, we sought to examine further the signal
transduction by the C1 and C3 containing isoforms of
FGFR2-IIIb to understand better why the FGFR2-C3
isoform is more transforming of HME cells. Our results
indicate that FGFR2-C3 is a constitutively active
receptor tyrosine kinase, leading to strong and sus-
tained activation of FRS2 and downstream signaling
pathways. By contrast, the FGFR2-C1 isoform
requires stimulation by KGF to achieve full activation.
KGF-induced activation of FGFR2-C1 is transient,
and results in a mobility shift of FRS2 that is not
observed when this signaling molecule is activated
by the C3 isoform of FGFR2. Site-directed mutagenesis
of the FGFR2-C1 carboxyl terminus indicated that
the removal of Tyr769 did not lead to more transform-
ing activity in the FGFR2-C1 isoform. In addition to
FGFR2 being highly overexpressed at the message
and protein levels, these findings strongly suggest
that the expression of alternatively spliced variants
of FGFR2, particularly those containing the C3
carboxyl terminus, is required to fully induce the




H16N2 cells are an immortalized human mammary epithe-
lial cell line that were immortalized by the human papilloma-
virus-16 genes E6, E7, and E5 (Band et al., 1990). The SUM-52
and H16N2 cells are cultured in Ham’s F12 medium under
serum-free conditions. The medium is supplemented with 0.1%
BSA, 0.5 mg/ml fungizone, 5 mg/ml gentamicin, 5 mM
ethanolamine, 10 mM HEPES, 5 mg/ml transferrin, 10 mM T3,
50 mM selenium, 1 mg/ml hydrocortisone, and 5 mg/ml insulin.
Vector-control H16N2 cells also grow in the presence of 10 ng/
ml EGF. Transduced H16N2 cells grow in G418-supplemented
media to maintain expression of the transgene. All cell culture
reagents were obtained from Sigma Chemical Co. (St. Louis,
MO).
Site-directed mutagenesis
Mutagenesis of FGFR2-C1 to FGFR2-C1-Y769F was per-
formed using the Stratagene QuikChange XL Site-Directed
Mutagenesis Kit (Stratagene, La Jolla, CA), according to the
manufacturer’s instructions. In short, the ‘‘tac’’ codon at base
2,900 was mutated to ‘‘ttc’’ in order to substitute a Phe for a Tyr
at amino acid 769. Primers were designed which amplified
the insert-containing plasmid (pNG), and introduced the
appropriate mutation. (Forward: TCACAACCAATGAG-
GAAttcTTGGACCTCAGCCAA and reverse: TTGGCTGA-
GGTCCAAgaaTTCCTCATTGGTTGTGA, with the target
codon denoted in bold, lower-case.) The kit provides PfuTurbo
DNA polymerase, which replicates both plasmid strands with
high fidelity. The plasmid is then transformed into XL10-Gold
ultracompetent cells (provided with the kit). We next
performed minipreps (Qiagen, Valencia, CA) and the prepared
DNA was sent for sequencing to the Wayne State University
DNA Sequencing Core. (Sequencing primers were forward:
ATGGATAAGCCAGCCAACTG and reverse: GAGGAAGG-
CATGGTTCGTAA, with each approximately 100 bp from the
mutation.) Sequencing verified introduction of the desired
mutation.
Development of FGFR2-C1-Y769F-expressing cell lines
The FGFR2-C1-Y769F-expressing pNG plasmid was trans-
fected intofnx-A viral packaging cells.fnx-A cells were plated
at 2 106 cells/60-mm dish 1 day prior to transfection. Cells
were transfected using the calcium phosphate method. Briefly,
fnx-A cells were incubated in 10% Dulbecco’s modified eagle
medium with 50 mM chloroquine for 5 min. A reaction mix of
5 mg DNA, 1 HEPES-buffered saline, and CaCl2 (JT Baker,
Phillipsburg, NJ) was added to fnx-A dishes. Media were
changed 8 h after transfection, and again 24 h later. Forty-
eight hours after transfection, viral particles were collected,
centrifuged, and filtered. Virus was frozen at 808C, then the
viral particles collected the following day (72 h post-transfec-
tion) were used to infect H16N2 human mammary epithelial
cells.
H16N2 cells were grown to approximately 30–50% con-
fluence and infected with prepared viral particles. In order to
aid in fusion of cell membranes, cells were also treated with
5mg/ml polybrene. Media were changed on the H16N2 cells 24 h
following infection. After 48 h, cells were now fed with selection
media, including G418. One 60-mm dish was grown in the
presence of EGF and one was grown without EGF, in order to
apply selection pressure for cells that have taken up the
mutant version of FGFR2-C1.
RT-PCR verification of FGFR2-C1-Y769F expression
Total RNA was isolated using the Qiagen RNeasy kit. RNA
was converted into cDNA via a reverse transcription reaction
with random hexamer primers, using the SuperScript First-
Strand Synthesis System for RT-PCR (Invitrogen, Carlsbad,
CA). Product was then used for amplification of FGFR2 using
gene specific primers to the conserved transmembrane domain
portion of the receptor (forward: AGCAAGCGCCTGGAAGA-
GAAAA and reverse: GGCTTATCCATTCTGTGTCCTTC).
The AccuPrime Pfx (Invitrogen) protocol was followed, using
35 cycles of 948C for 30 sec, 568C for 1 min, and 728C for 1.5 min,
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with a final extension at 728C for 10 min. RT-PCR product was
then run in a 0.8% agarose gel for analysis.
FGFR2 Western blots
Cells were rinsed twice with ice cold 1 PBS and then lysed
on ice with a buffer consisting of 50 mM Tris-HC1, pH 8.5,
150 mM NaCl, 1% Nonidet P-40 (ICN Biomedical, Inc., Aurora,
OH), and 5 mM EDTA, supplemented with 5 mM sodium
orthovanadate, 10 mM sodium pyrophosphate, 50 mg/ml
phenylmethsulfonyl fluoride (PMSF), 20 mg/ml aprotinin, and
10 mg/ml leupeptin. Lysates were spun at 20,800g at 48C for
10 min and then analyzed for protein using a modified Lowry’s
method. For detection of FGFR2-C1 mutant and wild type
variants, 100 mg of whole cell lysates were resolved in
7.5% polyacrylamide gels, transferred to PVDF membrane
(Millipore Corporation, Bedford, MA) and probed with an anti-
FGFR2 antibody (Santa Cruz Biotechnology, Inc., Santa Cruz,
CA). This antibody is specific for the C1 carboxyl terminus of
FGFR2, and therefore does not detect the FGFR2-C3 isoform.
The blots were developed with ECL Western Blotting Sub-
strate (Pierce, Rockford, IL) and exposed to film.
Assessment of monolayer growth
Cells were plated into 6-well dishes at 3.5 104 cells/well, in
serum-free media in the presence of insulin and the absence of
EGF. Cells were fed every other day with the appropriate
media. The concentration of FGFR inhibitor PD173074 was
1 mM and KGF-treated cells were treated with 25 ng/ml KGF
(Sigma) plus 2 mg/ml heparin. Plating efficiency cell counts
were determined 24 h after originally plating the cells, and this
was considered day 0 for the experimental groups. The number
of cells was determined by counting isolated nuclei with a
Coulter Counter at day 0, 3, and 7 after plating. All
experiments were done in duplicate, twice.
Growth in soft agar
A bottom layer of 1:1 Ham’s F-12 serum free medium and
1% agarose was poured and allowed to solidify. A 1 ml
suspension of 1 105 cells in a 0.3% agarose solution was
plated into 6-well dishes and fed every other day by adding 1 ml
of medium on top of the soft agar. Cells were maintained in
serum-free medium, in the presence of insulin and the absence
of EGF. After 2 weeks, excess medium was carefully removed
from the wells, and 1 mg/ml solution of p-iodonitrotetrazolium
violet (Sigma) was added to the wells overnight to stain for
viable cells. Stained viable cell colonies were photographed the
following day.
FRS2 Western blots
Cells were treated for 10 min in the presence or absence of
25 ng/ml KGF (Sigma)þ 2 mg/ml heparin. Cells were lysed as
described above, and 1 mg whole cell lysate was affinity
precipitated with p13suc1-agarose-conjugated beads (Upstate,
Lake Placid, NY). Samples were run in an SDS–PAGE gel and
blotted onto PVDF membrane. The FRS2 antibody was
purchased from Santa Cruz, and the anti-phosphotyrosine
antibody (4G10) is from Upstate. These blots were developed
via ECL. All Western blots are representative of at least two
different experiments.
For Figures 1 and 6, cells were exposed to KGF and heparin
for 10 min, then the plates were rinsed and fresh media
were added, without KGF. The cells were lysed following the
indicated number of hours after removal of KGF, and the
Western blot was performed as described above. Quantification
Fig. 1. Time course of FRS2 tyrosine phosphorylation after KGF
stimulation of FGFR2-C1 and C3 cells. A: FGFR2-C1 and C3 cells
were either not treated (nt), or treated with 25 ng/ml KGF and 10 mg/
ml heparin for 10 min (K). The remaining samples were treated with
KGF for 10 min, rinsed, and then lysed after the indicated number of
hours. FRS2 was affinity precipitated with p13suc1-agarose-conjugated
beads, and the Western blot was probed with a phosphotyrosine
antibody. B: This figure shows differently exposed blots for each cell
line. The FGFR2-C1 half of the blot was exposed for 10 min and the C3
for 1 min. Quantification of the intensities of the data shown is
depicted in the graph below each blot.
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was performed utilizing Bio-Rad (Hercules, CA) Quantity One
software.
Figure 7 shows cells treated with or without KGF and
heparin for 10 min. Hundred micrograms of whole cell lysate
was run directly into an SDS–PAGE gel. These blots were
probed with phosphospecific FRS2 antibodies, purchased from
Cell Signaling (Beverly, MA), that recognize pTyr196 and
pTyr436 of FRS2.
Erk Western blots
Cells were treated 24 h in the presence or absence of 1 mM
PD173074, or 10 min in the presence or absence of 25 ng/ml
KGFþ 2 mg/ml heparin. Cells were lysed as described above,
and 100 mg whole cell lysate was run in an SDS–PAGE gel and
blotted onto PVDF membrane. Antibodies used were anti-Erk1
and phospho-Erk (Santa Cruz). These blots were also devel-
oped via ECL.
Phosphothreonine FRS2 analysis
Cells were treated with the MAPK inhibitor U0126
(Promega, Madison, WI) at 5 mM for 30 min, or 10 min with
KGF, and heparin. We have previously observed that 30 min of
5 mM U0126 treatment abrogates phosphorylation of Erk,
indicating inhibition of MEK (data not shown). Cells were lysed
as described above, and 1 mg of whole cell lysate was
immunoprecipitated with the FRS2 antibody (Santa Cruz).
Samples were run in an SDS–PAGE gel and blotted onto PVDF
membrane. The blots were probed with antibodies against
phosphotyrosine (Upstate) or phosphothreonine followed by a
proline (Cell Signaling).
RESULTS
To investigate the transforming potential of alterna-
tively spliced FGFR2 variants expressed by the SUM-52
breast cancer cells, we previously stably overexpressed
the full-length FGFR2-C1 and FGFR2-C3 isoforms into
H16N2 human mammary epithelial cells.
FRS2 activation followed by KGF stimulation
As our early work showed that FRS2 is constitutively
highly tyrosine phosphorylated in the FGFR2-C3-
expressing H16N2 cells, and only weakly phosphory-
lated in the FGFR2-C1 cells, we further analyzed the
activation of this signaling molecule. We have observed
previously that KGF induced an increased tyrosine
phosphorylation and upward electrophoretic mobility
shift of FRS2 in the FGFR2-C1-expressing cells (Moffa
et al., 2004). This result was observed with as brief as a
10-min exposure of the FGFR2-C1 cells to KGF, as well
as continuous KGF stimulation overnight (approxi-
mately 14 h). However, it was unclear how long the
FGFR2 isoforms remained activated after stimulation
with exogenous ligand.
In order to address this question, FGFR2-C1 and C3
cells were treated with KGF for 10 min, the media
changed, and the cells lysed after varying amounts of
time. FRS2 was affinity precipitated from cell lysates
with p13suc1-agarose-conjugated beads, and levels of
FRS2 tyrosine phosphorylation were assessed (Fig. 1A).
As we have observed previously, the basal level of
tyrosine phosphorylated FRS2 was much higher in the
FGFR2-C3-expressing cells than FGFR2-C1. Clearly,
both cell lines responded to KGF stimulation, showing
increases in the tyrosine phosphorylation of FRS2
following 10 min exposure to KGF. Figure 1B shows
differently exposed films from the same blot, and
quantification of band intensity. In order to appropri-
ately visualize and compare the tyrosine phosphory-
lated levels of FRS2 in the FGFR2-C1 versus C3 cells,
the samples from the FGFR2-C3-expressing cells were
exposed to film for one-tenth the time as the C1 samples.
Furthermore, even with the prolonged exposure time,
the basal level of tyrosine phosphoryated FRS2 in the
FGFR2-C1-expressing cells was undetectable, and thus
not quantifiable. Therefore, these data show that FRS2
is constitutively tyrosine phosphorylated to high levels
in the FGFR2-C3 cells, regardless of the presence of
ligand. Even though KGF induces an enhanced inten-
sity of tyrosine phosphorylated FRS2 that is subject to
downregulation upon removal of ligand, the basal levels
remain high in the presence or absence of KGF. In
contrast, the FGFR2-C1 cells were dependent on
continuous KGF stimulation to achieve high levels of
FRS2 tyrosine phosphorylation.
Site-directed mutation of FGFR2-C1
carboxyl terminus
Due to our observations of the dramatically different
transforming potential of FGFR2-C3 versus FGFR2-C1,
we next sought to analyze the structural differences
between the proteins. A logical target was Tyr769, as
this potentially important signaling residue is present
on the FGFR2-C1 carboxyl terminus, and absent from
C3 (Itoh et al., 1994). In addition to binding PLCg, Cross
et al. have shown that phosphorylated Tyr766 on
FGFR1 binds to the Shb adapter protein, contributing
to MAPK activation (Mohammadi et al., 1991; Cross
et al., 2002). Further, data from Lax et al. (2002)
indicated that MAPK threonine phosphorylates FRS2,
which serves as a negative feedback loop and leads to a
decrease in tyrosine phosphorylation of FRS2. Since
only FGFR2-C1 has the appropriate residue to bind to
Shb, we hypothesized that this mechanism of negative
regulation of FRS2 via MAPK might be responsible for
the controlled signaling in the FGFR2-C1-expressing
cells, as compared to the robust constitutive level of
tyrosine phosphorylated FRS2 observed in cells expres-
sing the FGFR2-C3 isoform lacking Tyr769.
To determine the importance of Tyr769 on the C1
carboxyl terminus, we performed site-directed muta-
genesis of tyrosine to phenylalanine. FGFR2-C1-Y769F
was created by PCR-based site-directed mutagenesis,
and verified by DNA sequencing. The mutant was
introduced into H16N2 human mammary epithelial
cells via a stable bicistronic retroviral infection using the
same pNG vector as the wild type FGFR2-C1 and C3
genes. Transduced cells were selected for resistance to
G418, and grown in serum-free medium supplemented
with insulin, in the presence or absence of EGF.
Expression of C1-Y769F message (tested via RT-PCR)
and protein (Western blotting) in the H16N2 cells was
validated and the data are shown in Figure 2A, B.
The C1-Y769F cells originally grown in the presence
of EGF were either propagated as individual clones, or
as a polyclonal population. YF#7 is representative of a
highly-expressing clone, and YFpc cells are the original
polyclonal population. Another clone, YF#8, was unable
to grow in the absence of EGF and, without this selection
pressure, eventually lost C1-Y769F expression entirely,
as shown in Figure 2B. YF-EGF cells were initially
selected directly for EGF-independent growth, and were
sustained as a polyclonal population. When these cells
were originally being selected, they grew more slowly
than the cells grown in the presence of EGF. At the
present time, all C1-Y769F-expressing cells are growing
robustly in the absence of EGF.
As growth factor independence is a hallmark of
transformation, we assessed the ability of FGFR2-C1-
Y769F cells to grow in medium lacking EGF. This is the
condition under which the FGFR2-C1 wild type,
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FGFR2-C3, and SUM-52 cells routinely grow, while
H16N2 cells normally depend on EGF for growth. We
analyzed EGF-independent growth of cells highly
expressing the C1-Y769F clone (YF#7), and compared
them to FGFR2-C1 wild type expressing cells, and cells
expressing the pNG empty vector. The growth curve in
Figure 3A shows that the C1-Y769F-expressing
cells grew at a similar rate in the absence of EGF
as cells expressing wild type FGFR2-C1. The C1-Y769F
cells grew and survived without EGF, whereas the pNG
empty vector expressing H16N2 cells did not, indicating
that this FGFR2 mutant induced growth factor inde-
pendent proliferation and survival, like the wild type
FGFR2-C1.
We next treated cells with the small molecule FGFR
kinase inhibitor PD173074 and assessed their growth
capacity. We observed that growth of the C1-Y769F-
expressing cells in EGF-free medium was blocked by the
FGFR inhibitor (Fig. 3B). The FGFR2-C1 cells’ growth
was also inhibited by PD173074, and the pNG empty
vector expressing cells were unaffected. This indicates
that the FGFR2-C1-Y769F and FGFR2-C1 wild type
expressing cells are dependent upon FGFR2 activity to
grow in the absence of EGF. Finally, we assessed the C1-
Y769F cells’ responsiveness to exogenous KGF, since
KGF is a natural ligand for FGFR2-IIIb. The data in
Figure 3C indicate that the C1-Y769F and FGFR2-C1
wild type cells displayed a slight growth advantage in
the presence of KGF in the media, in the absence of EGF.
However, the SUM-52 breast cancer cells and H16N2
cells overexpressing FGFR2 required neither EGF nor
KGF for growth or survival, as evidenced by their
routine culture in serum-free medium lacking exogen-
ous EGF or KGF. In addition, we have determined by
ELISA that these cells do not secrete KGF, ruling out an
autocrine activation of FGFR2 by KGF (data not shown).
However, FGFR2b also binds FGF1, 3, 10, and 22,
allowing the possibility of an autocrine loop with one of
these other ligands. Overall, our phenotype data suggest
that H16N2 cells overexpressing FGFR2-C1-Y769F,
wild type FGFR2-C1, or C3 proliferate in the absence
of exogenous EGF or KGF in monolayer.
To study further the transformation of the FGFR2-
C1-Y769F mutant expressing cells, we tested their
ability to grow under anchorage-independent condi-
tions. Cells were plated in soft agar, and cultured in
media containing insulin and lacking EGF. Viable cell
colonies were stained and photographed after 2 weeks.
Figure 4 shows that the C1-Y769F-expressing cells were
able to survive and proliferate under anchorage-inde-
pendent conditions in the absence of EGF, similarly to
the wild type FGFR2-C1. In contrast, the pNG empty
vector expressing cells did not survive in soft agar in
EGF-free medium. These data suggest that overexpres-
sion of the mutant C1-Y769F version of FGFR2 induces
transformed phenotypes in human mammary epithelial
cells, comparable to FGFR2-C1 wild type.
Signal transduction by FGFR2-C1-Y769F
Next, we performed Western blots examining the
phosphorylation status of FRS2 in the FGFR2-C1-
Y769F-expressing cells, as compared to wild type
FGFR2-C1, C3, and SUM-52 cells. FRS2 was affinity
precipitated from cell lysates, and the levels of FRS2
protein and tyrosine phosphorylation were assessed.
Figure 5 shows that basal FRS2 tyrosine phosphoryla-
tion was low in the C1-Y769F mutant expressing cells,
similar to the cells expressing wild type FGFR2-C1. In
contrast, constitutive tyrosine phosphorylation of FRS2
in the FGFR2-C3-expressing cells was much higher.
Upon KGF stimulation, the tyrosine phosphorylation
and the apparent molecular weight of FRS2 increased in
the FGFR2-C1-Y769F and C1 wild type cells. Tyrosine
phosphorylation of FRS2 in the FGFR2-C3-expressing
cells was also increased in the presence of KGF, with the
basal level already high. The pNG empty vector
expressing H16N2 cells showed no tyrosine phosphor-
ylation of FRS2 in the presence or absence of KGF, as
expected. SUM-52 breast cancer cells displayed robust,
constitutive tyrosine phosphorylation of FRS2 with or
without KGF. These results suggested that signaling
from the mutant Y769F variant of FGFR2-C1 did not
mimic the signaling capacity of the FGFR2-C3 isoform.
Instead, both mutant C1-Y769F and wild type FGFR2-
C1-expressing cells depended on KGF to induce a high
level of tyrosine phosphorylation of FRS2, as compared
to the high constitutive level seen in the FGFR2-C3-
expressing cells.
We next sought to analyze the time course of FRS2
deactivation after withdrawal of KGF in the FGFR2-C1-
Y769F-expressing cells. This experiment was performed
in an identical manner to that shown in Figure 1, with
the cells exposed to KGF for 10 min, then lysed after
varied amounts of time and FRS2 tyrosine phosphoryla-
tion studied. Figure 6 shows that, in parallel to wild type
FGFR2-C1-expressing cells, the levels of FRS2 phos-
photyrosine in the untreated mutant cells were unde-
tectable, and they displayed a robust response to KGF
stimulation. Once again, this result more closely mimics
Fig. 2. Expression of FGFR2-C1-Y769F into H16N2 cells. A: RT-PCR
analysis of message levels of C1-Y769F. Numbered samples are
individual clones, and ‘‘pc’’ denotes a polyclonal population. ‘‘No RT’’
samples were run without reverse transcriptase enzyme. C1 repre-
sents wild type FGFR2-C1, and H16 are untransduced H16N2 cells.
B: This Western blot is whole cell lysate of the indicated samples,
blotted with an FGFR2 antibody. The antibody specifically recognizes
the FGFR2-C1 carboxyl terminus, so the FGFR2-C3 lane is blank.
The ** represents the full-length FGFR2-C1 isoform, and * is the
glycosylated version of that isoform. The other arrows denote the
additional C1-containing FGFR2 isoforms expressed by the SUM-52
cells. The YF#7 and YF#8 cell lines were cloned from H16N2 cells
infected with FGFR2-C1-Y769F, and originally cultured in the
presence of EGF. Clone YF#8 was unable to survive in the absence
of EGF, and therefore did not show expression of FGFR2-C1-Y769F.
YFpc cells are a polyclonal population of cells originally cultured with
EGF. YF-EGF cells were initially cultured in the absence of EGF.
Currently, all FGFR2-C1-Y769F-expressing cells are cultured in the
absence of EGF.
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that observed in the FGFR2-C1-expressing cells, with
FGFR2-C1-Y769F cells not able to express the high,
sustained level of FRS2 tyrosine phosphorylation
detected in the FGFR2-C3 cells in the absence of ligand.
These results also confirm and extend our observations
that activation of both mutant and wild type FGFR2-C1
isoforms results in an FRS2 mobility shift upon KGF
stimulation that is associated with a rapid loss of
tyrosine phosphorylated FRS2.
Tyrosine phosphorylated FRS2 is known to interact
directly with Grb2 and Shp2, leading to downstream
activation of the PI3-K and MAPK pathways. Phospho-
tyrosines 196 and 436 on FRS2 are binding sites for Grb2
and Shp2, respectively (Hadari et al., 1998; Kouhara
et al., 1997). Western blots of whole cell lysate protein
indicate that both tyrosines 196 and 436 were constitu-
tively phosphorylated in H16N2 cells expressing the
FGFR2-C1-Y769F mutant, wild type FGFR2-C1, and
C3, as well as the SUM-52 breast cancer cells (Fig. 7).
Neither of these FRS2 tyrosines was phosphorylated in
H16N2 cells expressing the pNG empty vector, as
expected. The basal levels of tyrosine phosphorylation
of Tyr196 and 436 in the FGFR2-C3-expressing cells and
the SUM-52 cells were notably higher than the cells
expressing either wild type or mutant FGFR2-C1.
Stimulation of the FGFR2-C1-Y769F and wild type C1
cells with KGF led to a dramatic increase in phospho-
tyrosine intensity, as well as an apparent molecular
Fig. 3. Growth curves of FGFR2-C1-Y769F cells. Cells were plated in
6-well dishes at 5 103 cells/well. Nuclei were isolated and automati-
cally counted after the indicated number of days. A: Ability of FGFR2-
C1-Y769F, C1 wild type, and empty vector (pNG) expressing cells to
grow in the absence of EGF. B: Growth curve of cells in the presence or
absence of 1 mM FGFR kinase inhibitor PD173074 (I). Please note that
all three treated cell lines, and the untreated pNG cells, were unable
to grow under these conditions, and thus the data overlap. Cells were
fed and treated every other day. C: Growth curve analysis of FGFR2-
C1-Y769F, C1 wild type, and pNG cells in the presence or absence of
25 ng/ml KGF and 10 mg/ml heparin (KGF). Cells were fed and treated
every other day.
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weight increase of the FRS2 protein, depicted in both
phospho-specific blots shown in Figure 7. These data
indicated that the basal level of tyrosine phosphorylated
FRS2 leading to activation of major downstream path-
ways was dramatically higher in FGFR2-C3-expressing
cells, as compared to mutant or wild type FGFR2-C1. In
all of the FGFR2 overexpressing cells tested, the FGFR
kinase inhibitor PD173074 completely abrogated the
phosphorylation of both sites on FRS2, indicating that
FGFR2 activity was required for FRS2 activation at
multiple sites (data not shown).
To study signaling downstream from FGFR2/FRS2,
we next analyzed activation of the MAPK pathway.
Phosphorylation of Erk-1 and 2 serves as an indication of
MAPK activity. Cells were untreated, treated for 24 h
with the FGFR kinase inhibitor PD173074, or treated
for 10 min with KGF. Cells were then lysed, and
subjected to Western blotting for Erk and phospho-
Erk. Data in Figure 8 suggest that Erk phosphorylation
is enhanced in the FGFR2-C1-Y769F and wild type C1-
expressing cells in the presence of KGF. Basal Erk
phosphorylation levels appear higher in the FGFR2-C1-
Y769F-expressing cells as compared to wild type
FGFR2-C1 cells. In this case, Erk activation by
FGFR2-C1-Y769F more closely mimics that observed
in the FGFR2-C3-expressing cells. However, both the
mutant and wild type FGFR2-C1-expressing cells
respond to KGF stimulation, whereas levels of Erk
phosphorylation in the FGFR2-C3-expressing cells
appear unchanged.
Erk phosphorylation in the FGFR2 overexpressing
H16N2 cells was only partially inhibited by the FGFR
kinase inhibitor, as we have observed previously (Moffa
et al., 2004). The residual levels of Erk phosphorylation
upon FGFR inhibition may be attributable to insulin-
mediated activity. The vector control pNG cells
Fig. 3. (Continued)
Fig. 4. Anchorage-independent growth of FGFR2-C1-Y769F and wild type FGFR2-C1-expressing cells.
Cells were grown for 2 weeks in soft agar as described in Materials and Methods. Samples were
maintained in serum-free media, in the presence of insulin and absence of EGF. Viable colonies were
stained and photographed.
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expressed a low level of constitutively phosphorylated
Erk, since these cells are cultured in the presence of both
insulin and EGF, whereas the FGFR2 overexpressing
cells are all cultured in the absence of EGF. Erk
phosphorylation in the pNG-expressing cells was unaf-
fected by KGF stimulation, nor was it blocked by FGFR
kinase inhibition (Fig. 8).
Together, these results indicate that the FGFR2-C1
isoform with Tyr769 mutated to a phenylalanine is not a
more transforming variant than the wild type FGFR2-
C1. Based on the literature, we assume that Tyr769,
homologous to Tyr766 on FGFR1, solely mediates the
interaction between the FGFR2 molecule and the
signaling proteins PLCg and Shb. However, the possi-
bility remains that either FGFR2-C1 or C3 may
otherwise interact with PLCg or Shb, independent of
Tyr769. Overall, our data suggest that preventing
interactions between FGFR2-C1 Tyr769 and either
PLCg or Shb did not create a receptor that mimics the
signaling capacity of the FGFR2-C3 isoform.
Threonine phosphorylation of FRS2
Finally, we sought to analyze the phosphothreonine
status of FRS2 in the H16N2 cells overexpressing the
FGFR2-C1 or C3 isoform, and the SUM-52 breast cancer
cells. Lax et al. (2002) have reported that there are eight
threonine residues on FRS2 that are sites for phosphor-
ylation by MAPK. Since we observed a significant
upward electrophoretic mobility shift of FRS2 upon
stimulation of FGFR2-C1-expressing cells with the KGF
ligand, we hypothesized that this apparent molecular
weight increase could be due to threonine phosphoryla-
tion of FRS2.
We utilized the MAPK inhibitor U0126 to assess the
role of MAPK signaling in the threonine phosphoryla-
tion of FRS2 in our cells. We observed that the p13suc1-
agarose-conjugated beads were unable to pull down
FRS2 in the presence of U0126, suggesting that the
association between FRS2 and p13suc1 was dependent
upon serine/threonine phosphorylation of FRS2 (data
not shown). Therefore, we immunoprecipitated FRS2
with an anti-FRS2 antibody and blotted with an
antibody specific for the sites threonine phosphorylated
by MAPK (pThr-Pro), as well as for tyrosine phosphor-
ylation. Cells were untreated, treated with the U0126
MAPK inhibitor for 30 min, or treated with KGF for
10 min. The phosphothreonine blot in Figure 9 indicates
that MAPK was indeed responsible for threonine
phosphorylating FRS2 in our cells, as the phosphoryla-
tion was completely abrogated by treatment with
U0126. The data suggest that FRS2 was highly
threonine phosphorylated in the SUM-52 cells, followed
by FGFR2-C3-expressing cells and C1, with no threonine
Fig. 5. Tyrosine phosphorylation of FRS2 in the FGFR2-C1-Y769F,
C1 wild type, C3, pNG expressing cells, and SUM-52 cells. Samples
labeled ‘‘nt’’ are not treated, and ‘‘K’’ lanes were treated with KGF and
heparin for 10 min. FRS2 was affinity precipitated and blots were
probed for phosphotyrosine or FRS2.
Fig. 6. Time course of FRS2 tyrosine phosphorylation after KGF stimulation of FGFR2-C1-Y769F cells.
As described in Figure 1, samples were not treated (nt) or treated with KGF and heparin and 10 min (K),
then lysed after the indicated number of hours. FRS2 was affinity precipitated and the blots were probed
for phosphotyrosine. The graphs below each blot show quantification of band intensities.
FGFR2 SIGNALING IN HUMAN MAMMARY EPITHELIAL CELLS 727
Journal of Cellular Physiology DOI 10.1002/jcp
phosphorylation of FRS2 occurring in the pNG empty
vector expressing H16N2 cells. Treatment of the
FGFR2-C1-expressing cells with KGF induced an
increase in the threonine phosphorylation of FRS2,
consistent with the increase in FRS2 molecular weight
upon ligand stimulation. The data in the phosphotyr-
osine blot indicate that blocking threonine phosphoryla-
tion of FRS2 caused the molecular weight of FRS2 in all
cells to be greatly decreased but had no effect on
phosphotyrosine levels (Fig. 9, lower). The U0126-
treated samples show a smear of molecular weight sizes
of FRS2, suggesting dephosphorylation occurred on
variable numbers of the eight threonine residues. This
result suggests that threonine phosphorylation of FRS2
is responsible for a significant molecular weight shift of
the protein, as expected. Although different molecular
weight sizes are present, the intensity of tyrosine
phosphorylation of FRS2 appears to remain unchanged
when MAPK was inhibited.
In all, the data presented here strongly suggest that
the full-length C3 isoform of FGFR2 expressed by the
SUM-52 breast cancer cells is highly transforming to
human mammary epithelial cells. Signaling generated
by FGFR2-C3 is constitutive, ligand-independent, and
robust, as demonstrated by tyrosine phosphorylation
levels of the adapter protein FRS2. In contrast, the
FGFR2-C1 isoform is dependent on KGF stimulation in
order to transiently achieve comparable signaling levels
as the C3 isoform. In the presence of KGF, FGFR2-C1
activation of FRS2 is associated with an electrophoretic
Fig. 7. Phosphospecific FRS2 Western blots in the presence or absence of KGF stimulation. FGFR2-C1-
Y769F, C1 wild type, C3, pNG, and SUM-52 cells were treated (K) or not (nt) with KGF for 10 min. Whole
cell lysate was assessed for levels of pTyr196 (top) or pTyr436 (bottom).
Fig. 8. Erk phosphorylation in cells treated with the FGFR inhibitor PD173074 or stimulated with KGF.
FGFR2-C1-Y769F, C1 wild type, C3, and pNG expressing cells were not treated (nt), treated with KGF
and heparin for 10 min (K), or with the FGFR inhibitor PD173074 for 24 h (I). Whole cell lysate was
assessed for levels of phospho-Erk or Erk-1.
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mobility shift not observed following FGFR2-C3 activa-
tion of FRS2. Furthermore, mutation of Tyr769 in the C1
carboxyl terminus did not significantly alter the signal-
ing capacity of the FGFR2-C1 isoform and, more
importantly, did not result in increased phosphotyro-
sine levels of FRS2, either constitutively or following
ligand stimulation. Finally, in addition to being tyrosine
phosphorylated, FRS2 also undergoes threonine phos-
phorylation in the SUM-52 cells and FGFR2 over-
expressing H16N2 cells. Upon MAPK inhibition,
threonine phosphorylation of FRS2 was abrogated and
the apparent molecular weight was dramatically
decreased, without affecting tyrosine phosphorylation
levels.
DISCUSSION
Gene amplification and alternative splicing contri-
bute to the overexpression of nine distinct FGFR2
isoforms in the SUM-52 breast cancer cells. Previous
studies of human mammary epithelial cells and NIH3T3
fibroblasts have suggested that overexpression of
FGFR2 isoforms with the C3 carboxyl terminus is more
transforming than FGFR2-C1 (Itoh et al., 1994; Moffa
et al., 2004). In this work, we sought to characterize
further the differences in signal transduction by
FGFR2-C1 and C3 variants, with specific emphasis on
responsiveness to ligand.
The FRS2 adapter protein plays a fundamental role in
propagating signals from FGF receptors. Ordinarily,
FRS2 gets tyrosine phosphorylated by FGFR upon
receptor activation from ligand binding. However, in
the SUM-52 breast cancer cells, FRS2 is constitutively
highly tyrosine phosphorylated in the absence of ligand.
This level of activation can be recapitulated by over-
expression of the FGFR2-C3 isoform into H16N2 HME
cells. Although FGFR2-C1-expressing cells display
phenotypes characteristic of transformation, these cells
cannot activate or sustain high levels of FRS2 tyrosine
phosphorylation in the absence of KGF, nor do they
express the full range of transformed phenotypes. The
time course data shown in Figure 1 clearly demonstrate
the difference between the basal and KGF-induced
tyrosine phosphorylated FRS2 levels in FGFR2-C1
versus C3-expressing cells. Whereas untreated
FGFR2-C1-expressing cells do not express detectable
levels of tyrosine phosphorylated FRS2, KGF stimula-
tion results in a dramatic increase in FRS2 phosphor-
ylation levels that diminishes with time after KGF
removal. The notable distinction in the FGFR2-C3 cells
is the robust level of FRS2 tyrosine phosphorylation in
non-stimulated cells. Although KGF transiently further
increases the level of tyrosine phosphorylated FRS2 in
the FGFR2-C3-expressing cells, the signaling potential
in the absence of ligand is not susceptible to the same
means of downregulation. Furthermore, these data
show the electrophoretic mobility shift of FRS2 upon
KGF stimulation of FGFR2-C1 cells, whereas the
apparent molecular weight of FRS2 remains unchanged
in treated versus untreated cells expressing FGFR2-C3.
After accumulating data describing the differences in
signaling between FGFR2-C1 and C3, the next logical
step was to investigate the structural difference
between these isoforms. We focused on tyrosine 769 in
the C1 carboxyl terminus for several reasons. This site is
the only known phosphorylated tyrosine present in the
C1 carboxyl terminus and absent from C3 (Itoh et al.,
1994; Mohammadi et al., 1996). Further, Tyr769 is
homologous to Tyr766 on FGFR1, which, upon phos-
phorylation is known to bind PLCg and/or Shb (Moham-
madi et al., 1991; Cross et al., 2002). The absence of this
site on FGFR2-C3 suggests that the interactions
between FGFR2-C1 and PLCg or Shb could negatively
regulate the signaling generated by the FGFR2-C1
isoform. Specifically, the association with Tyr769 and
Shb piqued our interest, since Shb has been reported to
be involved in activating the MAPK pathway. Evidence
in the literature suggests that threonine phosphoryla-
tion of FRS2 by MAPK decreases FRS2 tyrosine
phosphorylation (Lax et al., 2002). Together, this led to
our hypothesis that activation of MAPK by FGFR2-C1
via Shb stimulates threonine phosphorylation of FRS2,
leading to the rapid loss of tyrosine phosphorylated
FRS2 observed following KGF stimulation. Therefore,
we hypothesized that mutating Tyr769 to a phenylala-
nine would lead to a version of FGFR2-C1 with a reduced
ability to activate MAPK resulting in decreased levels of
threonine phosphorylated FRS2, and enhanced levels of
tyrosine phosphorylated FRS2, making it more similar
to FGFR2-C3.
Our data analyzing the C1-Y769F mutant indicate
that disrupting the predicted PLCg and Shb interaction
site did not enhance FGFR2-C1 signaling activity.
Rather, the C1-Y769F mutant was as transforming to
HME cells as the wild type FGFR2-C1, and was able to
similarly activate FRS2. Neither the wild type nor
mutant FGFR2-C1 isoform stimulated basal FRS2
Fig. 9. Phosphothreonine analysis of FRS2 in the presence or absence of the MAPK inhibitor U0126.
SUM-52, FGFR2-C1, C3, and pNG expressing cells were untreated (nt), treated with 5 mM of the MAPK
inhibitor U0126 for 30 min (U), or treated with KGF for 10 min (K). FRS2 was immunoprecipitated, and
the blot was probed for (top) phosphothreonine (pThr-Pro) or phosphotyrosine (lower).
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tyrosine phosphorylation to levels as robust as observ-
ed in FGFR2-C3-expressing cells. This suggests that
Tyr769 alone does not affect the ability of FGFR2-C1 to
induce and maintain downstream signaling pathway
activation. Even when overexpressed, the wild type or
mutant FGFR2-C1 isoform behaved in a manner more
similar to normal, controlled receptor signaling, as
opposed to the constitutive, ligand-independent signal-
ing activated by the FGFR2-C3 isoform.
Prior studies have described mutating the homolo-
gous PLCg-binding site on FGFR1, Tyr766, and sug-
gested that FGFR1 signaling does not depend on
activation of this pathway. Mohammadi et al. (1992)
and Peters et al. (1992) originally showed that mutation
of Tyr766 on FGFR1 led to the expected decrease in
PLCgactivity and decreased activation of protein kinase
C, without abrogating FGFR1-mediated mitogenesis.
In addition, FGFR1 site-mutated at Tyr766 remained
capable of inducing chemotaxis of endothelial cells and
neuronal differentiation of PC12 cells, as reported by
Clyman et al. (1994), Spivak-Kroizman et al. (1994) ,and
Landgren et al. (1998). Concurrent with our generating
and studying FGFR2-C1-Y769F, Ceridono et al. (2005)
reported generation of the same mutant, which they
overexpressed in NIH3T3 and HeLa cells. Their data
suggested that the FGFR2-Y769F mutation negatively
affected phosphorylation of FRS2 by FGFR2-C1 and
activation of MAPK, yet did not change the endocytosis
of FGFR2. In contrast, Sorokin et al. (1994) published
data indicating that Tyr766 on FGFR1 was involved in
the induction of receptor internalization, downregula-
tion, and degradation.
As mentioned above, our data show that FGFR2-C1
and C3-expressing cells exhibit a considerable differ-
ence in their levels of tyrosine phosphorylated FRS2.
To further analyze the activation of the FRS2 adapter
protein, we also examined threonine phosphorylation.
We found that the levels of FRS2 threonine phosphor-
ylation were lower in the FGFR2-C1-expressing cells,
as compared to FGFR2-C3 and SUM-52 cells. In the
presence of KGF stimulation, molecular weight and
threonine phosphorylation levels of FRS2 were drama-
tically increased in the FGFR2-C1-expressing cells, and
not FGFR2-C3. The threonine phosphorylation of FRS2
in all of the cells is dependent upon MAPK activity. The
comparably low level of basal FRS2 threonine phosphor-
ylation in the FGFR2-C1 cells was unexpected in light of
the data in the literature. Lax et al. (2002) proposed that
FRS2 threonine phosphorylation is mutually exclusive
with tyrosine phosphorylation of the protein, thus
hypothesizing that threonine phosphorylation of FRS2
decreases its ability to serve as a docking molecule for
downstream signal activation. Rather than a mutual
exclusivity between threonine and tyrosine phosphor-
ylation of FRS2 in our cells, we observed proportionality.
The cells with the highest level of tyrosine phosphory-
lated FRS2, SUM-52, also expressed the highest level of
threonine phosphorylated FRS2. Further, tyrosine
phosphorylation levels of FRS2 remained the same
regardless of changes to threonine phosphorylation
status that resulted from MAPK inhibition (Fig. 9).
These important observations led to a hypothesis
proposing that FGFR2-C1 and FGFR2-C3 modify the
FRS2 adapter protein in a fundamentally different
manner. There are six tyrosine and eight threonine
residues on FRS2 that are known to be sites for
phosphorylation (Kouhara et al., 1997; Hadari et al.,
1998; Lax et al., 2002). We propose that FGFR2-C1 and
FGFR2-C3 activate these sites in an inherently different
way, leading to differential downregulation of tyrosine
phosphorylated FRS2, possibly via ubiquitin-mediated
degradation or dephosphorylation. This is consistent
with the observation that the level of tyrosine phos-
phorylated FRS2 persists at a high intensity in the
FGFR2-C3-expressing cells. We observed KGF-induced
increases in FRS2 tyrosine phosphorylation in both
FGFR2-C1- and C3-expressing cells, with levels
decreasing after ligand removal. However, the high
basal level of tyrosine phosphorylated FRS2 in the
FGFR2-C3 cells remained unchanged, suggesting that a
different mechanism of FRS2 activation and deactiva-
tion is employed by cells expressing the FGFR2-C3
isoform whether in the presence or absence of ligand. By
contrast, the FGFR2-C1 isoform is only fully activated in
a ligand-dependent manner. Additionally, tyrosine
phosphorylated FRS2 in KGF-stimulated FGFR2-C1
cells migrates at a higher apparent molecular weight
than FRS2 in the FGFR2-C3 cells, even in the presence
of KGF. This would further suggest that phosphoryla-
tion, or other posttranslational events, might be taking
place on FRS2 in the FGFR2-C1 cells differently
from the C3-expressing cells, resulting in rapid down-
regulation of tyrosine phosphorylated FRS2. Intensive
proteomic analyses of FRS2 under different conditions
in the FGFR2-C1- and C3-expressing cells could reveal
the different modifications of FRS2 by each receptor
isoform.
Normal human mammary epithelial cells express
only full-length FGFR2 isoforms with the C1 carboxyl
terminus. In contrast, the SUM-52 human breast cancer
cells highly overexpress nine distinct isoforms of
FGFR2, which include three different carboxyl termini.
Overexpression of the full-length FGFR2-C3 isoform
into HME cells leads to robust activation of downstream
signaling, as evidenced by high levels of constitutively
tyrosine phosphorylated FRS2 in the absence of ligand,
whereas cells expressing FGFR2-C1 required constant
stimulation with KGF to achieve and maintain similar
activation. It is important to recall that the C1 and C3
carboxyl termini are expressed by different exons; C3 is
not a truncated version of C1 (Itoh et al., 1994). Clearly,
this FGFR2 alternative splicing event allowing the
inclusion of the exon for the C3 carboxyl terminus
conferred a growth advantage contributing to the
transformation of the SUM-52 breast cancer cells. The
FGFR2-C1 and C3 variants studied here are identical in
their ligand-binding domain, yet display dramatically
different dependency upon ligand for activating down-
stream signal transduction. Therefore, these data
strongly suggest that the specific presence of FGFR2
isoforms with the C3 carboxyl terminus is fundamental
to the transformed phenotypes of the SUM-52 cells, and
other cancer cells in which alternatively spliced FGFR2
is activated by gene amplification.
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